前立腺がん治療薬が白血病にも効果の可能性(Two Drugs That Treat Prostate Cancer May Also Be Effective Against Leukemia)

ad

2025-11-13 ペンシルベニア州立大学(Penn State)

ペンシルベニア州立大学の研究チームは、前立腺がん治療薬2種が白血病にも有効である可能性を発見した。対象となったのは、前立腺がんで用いられる アンドロゲン受容体(AR)阻害薬PARP阻害薬。研究者らは、大規模遺伝子データと薬剤反応データを統合し、白血病細胞の一部が前立腺がん細胞と共通の脆弱性を持つことを突き止めた。特に、ARシグナル関連経路が白血病でも活性化している症例では、AR阻害薬が白血病細胞の増殖を抑える可能性があることが示された。また、PARP阻害薬もDNA修復経路を標的として白血病細胞に効果を持つ可能性が示唆された。研究チームは、これら薬剤が既に承認済みで安全性プロファイルが確立している点から、白血病への「薬剤再利用(ドラッグリポジショニング)」として比較的早期に臨床研究へ展開できると期待している。今後は、白血病のどの分子サブタイプが最も恩恵を受けるかが焦点となる。

<関連情報>

急性骨髄性白血病における新たな介入標的としてのアンドロゲン受容体シグナル伝達 Androgen receptor signaling as a new target for intervention in acute myeloid leukemia

Fenghua Qian, Deborpita Sarkar, Brooke E. Arner, Vanessa M. Peduzzi, Yuting Bai, Baiye Ruan, Bei Jia, Hong Zheng, Robert F. Paulson, K. Sandeep Prabhu
Blood Advances  Available online: 26 September 2025
DOI:https://doi.org/10.1182/bloodadvances.2024012639

Key points

  • AR is expressed at high levels in leukemia cells isolated from the murine preclinical model as well as patient-derived AML cells.
  • Inhibition of AR signaling downregulated RTK/GAB2, PI3K/AKT/MTOR, and SRC/HIF-1α signaling pathways in AML stem cells.

Abstract

In addition to their role in development, sex hormones and their cognate receptors play an important role in various malignancies. Using a murine model of human MLL-AF9 induced acute myeloid leukemia (AML), we discovered that high Androgen receptor (AR) expressing leukemia initiating cells (LICs) when transferred into either male or female recipients resulted in more severe disease than low AR-expressing LICs. AR expression was significantly increased in female LICs compared to male LICs. This difference was confined to the LICs and not present in normal bone marrow cells. AML cells from both sexes relied on AR signaling via different mechanisms—females had high AR with low ligand, males, low AR with high ligand. AR expression was linked to EPHA7-associated PI3K/AKT/MTOR and SRC/HIF-1α pathways. Use of the two US FDA approved drugs for prostate cancer, ARN509, an AR antagonist and finasteride, which inhibits the pathway that produces dihydrotestosterone, resulted in significant remission with increased survival of AML mice. ARN509 and finasteride also showed pro-apoptotic effect in patient-derived AML cells and in a humanized AML model in NSG mice. These data support a drug repurpose effort to use anti-androgen therapy to improve the efficacy of AML treatments.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました